Rigel Pharmaceuticals (RIGL) Cash from Financing Activities (2010 - 2026)

Rigel Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$10.9 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 2355.99% year-over-year to -$10.9 million; the TTM figure through Mar 2026 stood at -$10.8 million (down 24.95% YoY), while the FY2025 annual figure was $601000.0, up 105.16% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$10.9 million, down from -$4.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $19.1 million in Q1 2023, with the low at -$10.9 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is -$373000.0 (2023), against an average of $174000.0.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities jumped 1911.31% in 2022, then sank 2355.99% in 2026.
• Rigel Pharmaceuticals' Cash from Financing Activities stood at -$2.1 million in 2022, then surged by 123.19% to $486000.0 in 2023, then jumped by 201.44% to $1.5 million in 2024, then plunged by 412.08% to -$4.6 million in 2025, then sank by 138.82% to -$10.9 million in 2026.
• Business Quant data shows RIGL's Cash from Financing Activities at -$10.9 million in Q1 2026, -$4.6 million in Q4 2025, and $4.3 million in Q3 2025.